<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119882</url>
  </required_header>
  <id_info>
    <org_study_id>EDICA_2019</org_study_id>
    <nct_id>NCT04119882</nct_id>
  </id_info>
  <brief_title>Early Detection of Myocardial Ischaemia in Suspected Acute Coronary Syndromes by Apo J-Glyc</brief_title>
  <acronym>EDICA</acronym>
  <official_title>Early Detection of Myocardial Ischaemia in Suspected Acute Coronary Syndromes by Apo J-Glyc as a Novel Pathologically-based Ischaemia Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycardial Diagnostics S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycardial Diagnostics S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the performance characteristics of Apo J-Glyc as a&#xD;
      novel biomarker for the early detection of myocardial ischaemia in patients with suspected&#xD;
      acute coronary syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This in vitro diagnosis clinical validation will test the Performance Characteristics of Apo&#xD;
      J-Glyc measured with a novel in vitro diagnostic (IVD) test. Blood samples from eligible&#xD;
      consenting subjects will be collected at hospital admission, throughout different post&#xD;
      admission times (1h, 3h, 24h and 72h or discharge). The quantification of circulating Apo&#xD;
      J-Glyc levels will be analysed in correlation with clinical data providing information about&#xD;
      Apo J-Glyc as an ischaemia biomarker and its diagnostic and 6-months prognostic value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Actual">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cut-off value point of Apo J-Gly levels at admission for the early diagnosis of cardiac ischaemia</measure>
    <time_frame>0 hour</time_frame>
    <description>Cut-off value point of Apo J-Gly levels at admission for the early diagnosis of cardiac ischaemia as compared to final diagnosis at discharge following routine practice to manage chest pain patients with possible ACS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cut-off value point of Apo J-Gly levels at admission for the early diagnosis of cardiac ischaemia</measure>
    <time_frame>1 hour</time_frame>
    <description>Cut-off value point of Apo J-Gly levels at admission for the early diagnosis of cardiac ischaemia as compared to final diagnosis at discharge following routine practice to manage chest pain patients with possible ACS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cut-off value point of Apo J-Gly levels at admission for the early diagnosis of cardiac ischaemia</measure>
    <time_frame>3 hours</time_frame>
    <description>Cut-off value point of Apo J-Gly levels at admission for the early diagnosis of cardiac ischaemia as compared to final diagnosis at discharge following routine practice to manage chest pain patients with possible ACS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Receiver Operating characteristic Curve (A-ROC curve)</measure>
    <time_frame>0 hour</time_frame>
    <description>Area under the Receiver Operating characteristic Curve will be used to determine the optimum clinical sensitivity and specificity. Results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Receiver Operating characteristic Curve (A-ROC curve)</measure>
    <time_frame>1 hour</time_frame>
    <description>Area under the Receiver Operating characteristic Curve will be used to determine the optimum clinical sensitivity and specificity. Results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Receiver Operating characteristic Curve (A-ROC curve)</measure>
    <time_frame>3 hours</time_frame>
    <description>Area under the Receiver Operating characteristic Curve will be used to determine the optimum clinical sensitivity and specificity. Results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>0 hours</time_frame>
    <description>Sensitivity results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>1 hours</time_frame>
    <description>Sensitivity results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>3 hours</time_frame>
    <description>Sensitivity results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>0 hour</time_frame>
    <description>Specificity results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>1 hour</time_frame>
    <description>Specificity results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>3 hours</time_frame>
    <description>Specificity results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV)</measure>
    <time_frame>0 hour</time_frame>
    <description>Negative Predictive Value results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV)</measure>
    <time_frame>1 hour</time_frame>
    <description>Negative Predictive Value results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV)</measure>
    <time_frame>3 hour</time_frame>
    <description>Negative Predictive Value results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV)</measure>
    <time_frame>0 hour</time_frame>
    <description>Positive Predictive Value results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV)</measure>
    <time_frame>1 hour</time_frame>
    <description>Positive Predictive Value results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV)</measure>
    <time_frame>3 hours</time_frame>
    <description>Positive Predictive Value results will be generated from subject's blood collected at different collection time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognosis and risk-stratification. Incidence of Major following Adverse Cardiac Event (MACE).</measure>
    <time_frame>From admission to up to 6 months</time_frame>
    <description>Subjects will be assessed for the in-hospital and 6-month incidence of any Major following Adverse Cardiac Event (MACE).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">404</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Positive for ischaemia</arm_group_label>
    <description>Blood test for 121 patients with confirmed cardiac ischemic event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative for ischaemia</arm_group_label>
    <description>Blood test for 283 patients with no cardiac ischemic event</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>New biomarker test</description>
    <arm_group_label>Negative for ischaemia</arm_group_label>
    <arm_group_label>Positive for ischaemia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals presenting to the Emergency Department (ED) with chest pain of suspected&#xD;
        cardiac origin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal or above 18 years old&#xD;
&#xD;
          -  Chest pain of suspected cardiac origin&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
          -  Able and willing to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior inclusion in the same study&#xD;
&#xD;
          -  Life expectancy less than 6 months&#xD;
&#xD;
          -  Previous inclusion in a therapy-related clinical trial (except clinical trials testing&#xD;
             Medical Devices such as stents and/or balloons)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judit Cubedo</last_name>
    <role>Study Director</role>
    <affiliation>Glycardial Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias (HUCA)</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>San Juan De Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminister Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East &amp; North Hertfordshire NHS Trust, Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Risk stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

